Novo Nordisk has reported that its oral semaglutide medicine showed non-inferiority compared to...
Trial finds new cell therapy safe for live cirrhosis treatment
Researchers from the MRC Centre for Regenerative Medicine at the UK's University of Edinburgh have reported positive results from a clinical trial that assessed a new cell therapy for liver cirrhosis.
CytoDyn to assess leronlimab in Phase II NASH trial
CytoDyn has secured US Food and Drug Administration (FDA) clearance to begin patient enrolment in a Phase II clinical trial of leronlimab (PRO 140) to treat non-alcoholic steatohepatitis (NASH).
Medicines Company’s inclisiran meets all endpoints in ORION-10 trial
The Medicines Company has reported positive results from the Phase III ORION-10 clinical trial, where cholesterol-lowering drug inclisiran met all primary and secondary endpoints in atherosclerotic cardiovascular disease (ASCVD) patients.
Novo Nordisk’s somapacitan shows favourable profile in GHD trial
Novo Nordisk has reported positive data from the Phase II REAL 3 clinical trial of somapacitan in children with growth hormone deficiency (GHD).
Alnylam begins Phase III study of patisiran in ATTR amyloidosis
Alnylam Pharmaceuticals has launched the Phase III APOLLO-B clinical trial to evaluate its RNAi therapeutic patisiran in adults suffering from transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.
Arrowhead reports initial data for cardiometabolic candidates
Arrowhead Pharmaceuticals has reported initial results from Phase I clinical trials of its RNAi-based cardiometabolic candidates ARO-APOC3 and ARO-ANG3 in patients with hypertriglyceridemia and dyslipidemia.
Medicines Company’s cholesterol drug inclisiran meets Phase III goals
The Medicines Company has announced that inclisiran met all primary and secondary efficacy endpoints in the Phase III ORION-11 clinical trial for lowering LDL-cholesterol (LDL-C).
Perspectum and ProPath partner on providing clinical trial expertise
Perspectum and ProPath have collaborated to enable pharmaceutical companies running clinical trials for liver disease to receive pathology and imaging expertise from one contract research organisation (CRO).
Synlogic terminates development of ammonia lowering drug
Synlogic has announced plans to suspend the clinical development of SYNB1020 following negative results from the candidate’s Phase Ib/IIa clinical trial in hyperammonemia patients.